Immuneering Corporation
IMRX Healthcare Biotechnology
Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00. In the quarter to June 2026, EPS grew 32.5% and free cash flow fell 74.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IMRX
Immuneering Corporation (IMRX) EV/Sales
As of 16 October 2026, Immuneering Corporation (IMRX) trades at a EV/Sales of 260×. Over the past ten years it has ranged from −106× (June 2024) to 968× (September 2025); the current reading is higher than 66% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 0.9× | (97.34%) |
| FY2021 | 34.1× | 137.58% |
| FY2020 | 14.4× | 0.00% |
| FY2019 | 14.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 0.9× | (99.82%) |
| Sep 2022 | 515× | 3,241.16% |
| Jun 2022 | 15.4× | (28.69%) |
| Mar 2022 | 21.6× | (36.58%) |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTTB Q32 Bio Inc. compare | −8.3× |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| FATE Fate Therapeutics, Inc. compare | 13.1× |
| ACIU AC Immune compare | 31.3× |
| SABS SAB Biotherapeutics, Inc. compare | 62.8× |
| SLGL Sol-Gel Technologies Ltd. compare | 127× |
| IMRX Immuneering Corporation | 260× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)